Analysts Have Spoken & Consensus Is in for Sage Therapeutics, Inc. (NASDAQ:SAGE)

Analysts on the sell-side are offering a consensus “Buy” rating on shares of Sage Therapeutics, Inc. (NASDAQ:SAGE).  Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.70 on the shares.  Based on a recent trade, the shares are hovering around $167.04 which, according to the Street, yields significant upside potential to the $202.50 consensus price target

The stock investing process may seem intimidating to those just starting out. New investors may have a lot to learn, and they may be wondering where to start. Because there are so many different stock picking strategies, it can be hard to find one specific one to latch on to. Keeping things simple might be a good way to approach the market for beginners. The day to day market happenings can get overwhelming not only for amateurs but professional investors as well. Finding that first little advantage can make all the difference when picking stocks. Many new investors may have the tendency to make too many trades at first without doing the proper research. Easing in to the process may give some much needed perspective for attaining long-term success in the stock market.

Wall Street firms hire hundreds of analysts who provide recommendations on stocks.  Typically, these analysts look at a company’s fundamentals, building financial models from this information in order to project future trends, specifically future earnings. 

These projections are then used as a basis for providing “buy” or “sell” recommendations.  Many investors consider these recommendations very seriously, and often times whenever an analyst changes their outlook on a stock, the price change almost immediately.

Many investors get into the stock market with unrealistic expectations. For whatever reason, they may have the mindset that snatching profits is easy. Thinking that profits can be doubled or tripled right away may lead the investor down the road of no return. Although the lucky few might hit some big winners right off the bat, these chances are quite low. Stocks tend to be volatile in the short-term. Unless investors have a game plan ready to capitalize on short-term movements, they may want to take a wider, longer-term approach. Trying to figure out which way the market will turn from one day to the next can be a highly frustrating procedure. Having the patience to thoroughly examine every trade can immensely boost the investor’s chances of surviving and thriving into the future.

Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will “beat” the artificially lowered estimate in order to get inexperienced investors to buy.

RSI 

Sage Therapeutics, Inc. (NASDAQ:SAGE)’s shares may have a significant upside to the consensus target of 202.50, but how has it been performing relative to the market?  The stock’s price is 167.04 and their relative strength index (RSI) stands at 46.87.  RSI is a technical oscillator that shows price strength by comparing upward and downward movements.  It indicates oversold and overbought price levels for a stock.  

Sage Therapeutics, Inc. (NASDAQ:SAGE) shares are moving 1.21% trading at $167.04 today,

On a typical market day there is no shortage of stock news. Investors are often tasked with trying to decipher which news is worth paying attention to and which isn’t. Not only is there plenty of swirling news, there are usually plenty of opinions that follow. Closely following market sentiment can be useful for some, but it may impede others when decisions need to be made. When it comes to dedicated stock research, taking shortcuts may result in disappointing portfolio performance. Investors have to be careful not to be tempted by the hot stocks of the day. Of course, maybe some of those stocks would fit well in the portfolio, but doing individual stock study can help confirm the addition.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*